United StatesUrad za upravljanje in proračun (OMB) je predlagal pravilo za revizijo postopka dodelitve zveznih nepovratnih sredstev, ki vključuje dodatek pregleda pred izdajo. Ta sprememba je sprožila veliko zaskrbljenost članov medicinske raziskovalne skupnosti, ki trdijo, da bodo povečane birokratske zahteve ovirale ameriške biomedicinske raziskave.
Ocena pristranskosti (Progresivno): V članku se predlagano pravilo OMB obravnava kot regulativno breme, ki negativno vpliva na biomedicinske raziskave, pri čemer se uporabljajo izrazi, kot so "dodatna birokracija" in "oviranje biomedicinskih raziskav v ZDA".
Zakaj dejstva (85): The article reports on a proposed rule from the Office of Management and Budget (OMB) and mentions opposition from the medical research community. While no primary source document was available, the information aligns with common reporting on this topic. The claim that the rule 'will destabilize bio
Zakaj objektivnost (70): The article presents the perspective of the medical research community as warning against the rule, but does not provide balanced viewpoints from proponents of the rule. The language used ('destabilize', 'additional red tape') suggests a critical tone toward the policy, indicating potential bias.
